Previous 10 | Next 10 |
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders PR Newswire Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respec...
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's PR Newswire Presenters, including Nobel Laureate in Medicine, to discuss innovative treatments for neurodegeneration Company t...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Synaptogenix Inc. (SNPX) is expected to report for Q1 2024
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology PR Newswire Acquires 25% stake in Cannasoul Analytics for up to $4 million to support R&D for cannabinoid- and psilocybin mushroom-based th...
Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease PR Newswire Bryostatin-1 benefits in severe Alzheimer's disease patients we...
2023-09-07 10:50:46 ET Penny Stocks: High Risk, High Reward Penny stocks, typically priced below $5, have become a popular choice for day traders due to their potential for rapid gains. These stocks can offer market-beating returns in a short period, making them attractive for those loo...
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study PR Newswire Positive changes in ALS gene expression and increased cellular viability met with statistical significance of p<.001 NEW YORK ...
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis PR Newswire Study will evaluate drug's potential neuro-restorative mechanism(s) of action for improving synaptic health...
2023-07-14 06:21:00 ET 3 Questions About Penny Stocks: Answered for 2023 Penny stocks, often undervalued by the mainstream investment world, present a unique opportunity for those willing to explore the less trodden paths of the financial markets. As we navigate through 2023, the penn...
News, Short Squeeze, Breakout and More Instantly...
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury PR Newswire Company holds exclusive rights to family of polyunsaturated fatty acid (PUFA) analogs New patent covers proprietary analogs in ...
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis PR Newswire Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , ...